Literature DB >> 16537188

Non-classical HLA-G antigen and its role in the cancer progression.

Piyush Tripathi1, Suraksha Agrawal.   

Abstract

Various changes take place during the progression of cancer, some of which are favorable for tumor development and may help to escape the immunosurvillance. These include changes in the microenvironment around the developing tumor, which could be produced in response to phenotypic alterations or could modulate the expression of certain markers of tumor development. One such newly discovered molecule is HLA-G, which has been found to have immunosuppressive and immunomodulatory roles in the cancer development. The regulatory sequences, as seen, may be induced by various factors that may be present in tumor microenvironment. A recent study has investigated the antigen -G as a marker of susceptibility to chemotherapy. Further, its expression on tumors and how it can be exploited for diagnosis and therapy is discussed in this article.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537188     DOI: 10.1080/07357900500524579

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  15 in total

1.  HLA-G expression in Merkel cell carcinoma and the correlation with Merkel cell polyomavirus infection.

Authors:  L M Parra; B G C Sartori; D R Fernandes; L R V Fachin; M R S Nogueira; A F F Belone; A J F Nunes; F C Souza-Santana
Journal:  Immunogenetics       Date:  2022-10-14       Impact factor: 3.330

Review 2.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

3.  Diagnostic and Biological Significance of KIR Expression Profile Determined by RNA-Seq in Natural Killer/T-Cell Lymphoma.

Authors:  Can Küçük; Xiaozhou Hu; Qiang Gong; Bei Jiang; Adam Cornish; Philippe Gaulard; Timothy McKeithan; Wing C Chan
Journal:  Am J Pathol       Date:  2016-04-07       Impact factor: 4.307

Review 4.  Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

Authors:  Sergio A Quezada; Karl S Peggs; Tyler R Simpson; James P Allison
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

5.  HLA-G, cytokines, and cytokine receptors in the non-aggressive basal cell carcinoma microenvironment.

Authors:  Andrezza Telles Westin; Luiz Gustavo Gardinassi; Edson Garcia Soares; João Santana Da Silva; Eduardo Antonio Donadi; Cacilda Da Silva Souza
Journal:  Arch Dermatol Res       Date:  2021-04-03       Impact factor: 3.017

Review 6.  Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association.

Authors:  Eduardo A Donadi; Erick C Castelli; Antonio Arnaiz-Villena; Michel Roger; Diego Rey; Philippe Moreau
Journal:  Cell Mol Life Sci       Date:  2010-11-24       Impact factor: 9.261

7.  The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model.

Authors:  Tereza Janotová; Marie Jalovecká; Marie Auerová; Ivana Švecová; Pavlína Bruzlová; Veronika Maierová; Zuzana Kumžáková; Štěpánka Cunátová; Zuzana Vlčková; Veronika Caisová; Petra Rozsypalová; Katarína Lukáčová; Nikol Vácová; Markéta Wachtlová; Jiří Salát; Jaroslava Lieskovská; Jan Kopecký; Jan Ženka
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

8.  Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors.

Authors:  Laura Menendez; L DeEtte Walker; Lilya V Matyunina; Kimberly A Totten; Benedict B Benigno; John F McDonald
Journal:  Mol Cancer       Date:  2008-05-22       Impact factor: 27.401

9.  Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia.

Authors:  W-H Yan; A Lin; B-G Chen; W-D Luo; M-Z Dai; X-J Chen; H-H Xu; B-L Li
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

Review 10.  Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity.

Authors:  Malgorzata Wachowska; Angelika Muchowicz; Jakub Golab
Journal:  Front Oncol       Date:  2015-07-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.